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SHIPiHematopoietic stem cell transplantation (HSCT) is a highly effective procedure enabling long-term survival for
patients with hematologic malignancy or heritable defects. Although there has been a dramatic increase in the
success rate of HSCT over the last two decades, HSCT can result in serious, sometimes untreatable disease due
to toxic conditioning regimens and Graft-versus-Host-Disease. Studies utilizing germline knockout mice have
discovered several candidate genes that could be targeted pharmacologically to create amore favorable environ-
ment for transplant success. SHIP1 deﬁciency permits improved engraftment of hematopoietic stem-progenitor
cells (HS-PCs) and produces an immunosuppressive microenvironment ideal for incoming allogeneic grafts. The
recent development of small molecule SHIP1 inhibitors has opened a different therapeutic approach by creating
transient SHIP1-deﬁciency. Here we show that SHIP1 inhibition (SHIPi) mobilizes functional HS-PC, accelerates
hematologic recovery, and enhances donor HS-PC engraftment in both allogeneic and autologous transplant set-
tings. We also observed the expansion of key cell populations known to suppress host-reactive cells formed dur-
ing engraftment. Therefore, SHIPi represents a non-toxic, new therapeutic that has signiﬁcant potential to
improve the success and safety of therapies that utilize autologous and allogeneic HSCT.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hematopoietic stem cell transplantation (HSCT) has historically
been successful in treating patients with cancer, autoimmune disease
(multiple sclerosis), and genetic disorders (thalassemia, sickle cell
disease) (Li and Sykes, 2012). Prior to HSCT, an intense conditioning
regimen is essential to reduce host tumor burden and/or auto-reactive
lymphocytes. The pro-inﬂammatory state triggered by pre-transplant
conditioning also enhances T and NK cell killing of residual tumor cells
particularly in the allogeneic setting (Paulos et al., 2007). However,
this same inﬂammatory milieu can promote donor or host T-cell reac-
tions that culminate in Graft-versus-Host-Disease (GvHD) or in graft re-
jection (Shlomchik, 2007, Ferrara et al., 2009). Many patients who
require HSCT do not have an appropriate human leukocyte antigen
(HLA) matched donor available. Additionally, HLA mismatch can be
beneﬁcial for cancer patients as an HLA mismatch results in increased
NK cell activity (Davies et al., 2002, Ruggeri et al., 2002). Therefore, a
major goal for optimizing HSCT is to enhance the engraftment of HLArsity, 750 E. Adams Street, 2204
. This is an open access article undermismatched grafts, while preventing, or reducing the undesired side ef-
fects triggered by the graft, the intense preconditioning regimens, or both.
SHIP1 and SHIP2 are two SH2-domain containing inositol 5′ phos-
phatases that oppose the activity of PI3K by converting Phosphatidyl-
Inositol(3,4,5)trisphosphate to Phosphadityl Inositol(3,4)bisphosphate.
PI3K promotes the survival, proliferation and effector functions in a
broad range of mammalian cell types, via activation of PDK1, Akt and
Tec family kinases (Yuan and Cantley, 2008). SHIP1 and SHIP2 have
also recently been shown to promote survival signals through the
recruitment and activation of enzymes including Akt and Irgm1
(Brooks et al., 2010; Tiwari et al., 2009).
SHIP1 ﬁrst emerged as a potential molecular target in HSCT when it
was found that both acute bonemarrow (BM) graft rejection and GvHD
were compromised in SHIP1 deﬁcient hosts (Wang et al., 2002).
Improved allogeneic BM engraftment in SHIP1 deﬁcient hosts results
from a constellation of immune phenotypes that include compromised
NK function (Wang et al., 2002; Wahle et al., 2006; Gumbleton et al., in
press), decreased numbers of T-cells in mucosal tissues (Kerr et al.,
2011; Park et al., 2014), and increased immunoregulatory cell numbers
such as myeloid derived suppressor cells (MDSCs) (Ghansah et al.,
2004; Paraiso et al., 2007), mesenchymal stem cells (MSC) (Iyer et al.,
2014a, 2014b), and Treg cells (Collazo et al., 2009; Kashiwada et al.,
2006; Locke et al., 2009). Parallel studies of the hematopoietic stemthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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taneouslymobilized to the peripheral blood due to a combined effect of
increased levels of granulocyte colony stimulating factor (G-CSF) and
matrix metallopetidase 9 (MMP-9), and a decrease in stromal-cell de-
rived factor 1 (SDF1) (Hazen et al., 2009). The loss of SHIP1 generates
two positive outcomes in the context of HSCT: mobilization of Hemato-
poietic Stem-Progenitor Cells (HS-PCs) to the periphery for harvesting,
and a ﬂux in the BMmicroenvironment that results in a suitable milieu
for incoming donor cell engraftment. In aggregate, these studies sug-
gested that recently identiﬁed SHIP1 inhibitors (Brooks et al., 2010,
2014; Fuhler et al., 2012) could eventually ﬁnd utility in various aspects
of both allogeneic and autologous HSCT.
Here, we investigated the potential of small molecule chemical
inhibition of SHIP1 (SHIPi) in vivo with the aminosteroid inhibitor
3AC for facilitating HSCT. We found that SHIPi promotes beneﬁcial
effects that could ﬁnd utility in both autologous and allogeneic trans-
plant settings as well as mobilization of HS-PCs. We hypothesized that
this instability in the bone marrow microenvironment would allow for
signiﬁcantly improved engraftment of an autologous BMgraft following
minimally ablative conditioning. As observed in genetic models, SHIPi
increased immunoregulatory cell populations (MDSC and Treg cells),
while disrupting NK cell effector function. The modulation of these im-
mune cell types also enhanced engraftment ofMajor Histocompatibility
Complex-I (MHC-I) mismatched BM following fully myeloablative
radiation conditioning. Therefore, SHIPi shows promise as a potential
non-toxic therapeutic to alter the immune environment for the
purpose of successful HSCT.
2. Materials and Methods
2.1. Mouse Strains
C57BL/6-CD45.2 (B6.2), C57BL/6-CD45.1 (B6.1) and BALB/c (H2d)
mice were purchased from Jackson Laboratories and Taconic and were
at least 8 weeks old at the time of experimentation. All mice were
housed at the Upstate Medical University Department of Laboratory
Animal Resources Facility for at least one week prior to start of experi-
mentations under conventional immunocompetent housing and feed-
ing conditions. All experiments were performed with the approval of
the Institutional Animal Care and Use Committee.
2.2. Synthesis and Veriﬁcation of 3AC and K190 Purity
See Supplemental experimental procedures for synthesis of 3α-
amino-5α-cholestane (3AC) and 3α-hydroxy-5α-cholestane (K190).
See Fig. S1A for structures of small molecules.
2.3. SHIPi Treatment of Mice
3AC (26.5 mg/kg) and K190 (24.3 mg/kg) were freshly emulsiﬁed
in vehicle immediately prior to administration to each mouse by intra-
peritoneal (i.p.) injection (100 μl per injection). Vehicle (0.3% (weight/
volume) Hydroxypropyl cellulose (Sigma) in Phosphate Buffered Saline
(1×PBS, Corning))wasﬁlter sterilized andwas also administered by i.p.
injection (100 μl per injection) in vehicle control mice. All injections
were performed once daily for 7 consecutive days unless otherwise
indicated. SHIPi or vehicle treatment of mice was performed on age-
matched and sex-matched groups.
2.4. Radiation Conditioning of Mice
Following SHIPi or vehicle treatment and prior to transplants, mice
received 300 Rads for minimally ablative conditioning, or 1100 Rads
(B6) or 800 Rads (BALB/c) for lethal irradiation conditioning by total
body irradiation from an X-ray source (RadSource, RS2000).2.5. ELISA Assays for G-CSF, MMP-9 and SDF1
Plasma levels of G-CSF, MMP-9 and SDF1-CXCL12 were determined
by ELISA (R&D Systems) according to the manufacturer's instructions.
2.6. HS-PC Mobilization and Congenic White Blood Cell (WBC)
Transplantation
Host B6.1 and BALB/c mice were treated with SHIPi or vehicle. On
day 8, Red Blood Cell (RBC) lysis was performed on blood obtained
from treated-mice, and live cells were counted. Untreated B6.2 and
BALB/c host mice were lethally irradiated, and were each injected
with 7.5 × 105 WBC from congenic vehicle-treated or SHIPi-treated
donor mice. For all harvest, the number of WBC donors was equivalent
or less than the number of hosts transplanted and did not compromise
viability of donors. Survival of mice receiving theWBC grafts was mon-
itored over a 4-month period.
2.7. Autologous, Congenic: Allogeneic and Allogeneic Bone Marrow
Transplant (BMT) and Engraftment by Flow Cytometry
Host B6.2mice were treated for 7 days with SHIPi or vehicle. On day
8, host mice were irradiated and received BMT as described in Table 1.
Engraftment was measured by ﬂow cytometry of RBC-lysed blood,
stained with an antibody cocktail containing anti-CD45.2, anti-H2Dd
or anti-CD45.1, anti-CD3ε, anti-Mac1, anti-GR1, and anti-CD19 for
the different types of transplants as indicated in Table 1. For acute
engraftment in congenic:allogeneic competitive BMT, host BM and
splenocytes were harvested on day 5 post-transplant and stained with
anti-H2Dd and anti-CD45.1 for analysis by ﬂow cytometry. Complete
description of each transplant is also described in Supplemental
methods.
2.8. Kinetic Analysis of NK, MDSC and Treg Cells
10 week old female B6.2 mice were treated daily for 0 to 10 days
with 3AC as described above. On each day (0 to 10 inclusively), 5 mice
were sacriﬁced, splenocytes were harvested, RBCs were lysed using
1× RBC Lysis buffer (eBioscience), counted and then stained with
anti-NK1.1, anti-Mac1 and anti-Gr1, or with anti-CD3ε and anti-CD4
then ﬁxed and stained with anti-FoxP3 as per manufacturer's recom-
mendation (eBioscience). Cells were analyzed by ﬂow cytometry as de-
scribed below. Frequency and absolute numbers of live NK cells and
MDSCs were compared to those observed in the splenocytes from the 5
uninjected mice harvested on day 0. Live CD4+FoxP3+ cells were
expressed as frequency of CD3ε+T-cells and compared to those onday 0.
2.9. Ex vivo NK Cell IFNγ Production Following Activating Receptor
Crosslinking
Splenocytes were harvested from 6 day SHIPi or vehicle treated
mice, red blood cells were lysed (1× RBC Lysis buffer, eBioscience)
and were incubated for 5 h alone (unstimulated), in anti-NK1.1
(PK136) antibody coated wells (NK1.1) or in the presence of 1.67 μg/
ml Phorbol Myristate Acetate (PMA) and 1 μg/ml ionomycin. In all
cases cells were incubated in the presence of GolgiPlug (BD Biosciences)
Fc receptors were blocked (2.4G2, BD Biosciences), surface receptors
were stained using anti-NKp46 or anti-DX5 and anti-CD3ε antibodies.
Cells were ﬁxed and permeabilized (BD Biosciences), Fc receptors
were blocked (2.4G2, BD Biosciences), and cells were stained for IFNγ
and analyzed via intracellular ﬂow cytometry.
2.10. Flow Cytometry and Blood Recovery
Dead cells (positively stained for DAPI dye) were excluded from all
the analyses, except for the NK cell analysis of INFγ and Treg cells that
Table 1
BM transplant schemes and engraftment analysis time frame.
Setting Host Donor Radiation BM cells Days of Txa Engraftment analysis
Autologous B6.2 B6.1 300 Rads 5 × 106 8, 9, 10 1–4 months
Congenic:allogeneic B6.2 B6.1
BALB/c
1100 Rads 5 × 106
5 × 106
8 5 days
Allogeneic B6.2 BALB/c 1100 Rads 1 × 106 or
2 × 106
8 1 week–4 months
a Tx: Transplants.
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Samples were acquired on an LSR-Fortessa or LSRII cytometers (BD Bio-
sciences) and analyzed using FlowJo software. All antibodies were pur-
chased from BD Biosciences or from eBiosciences. Blood component
recovery was monitored by a Hemavet 950S automated blood cell
analyzer (Drew Scientiﬁc).
2.11. Statistics
All statistical analyses were performed using GraphPad Prism 5.0.
2.12. Funding
This work was supported by grants from the NIH (RO1 HL072523,
R01 HL085580, R01 HL107127) and the Paige Arnold Butterﬂy Run.Fig. 1. SHIP1 inhibition mobilizes hematopoietic stem-progenitor cells. (A) G-CSF, MMP-9 and
7-day treatment with SHIPi [n = 5, t-test ***p b 0.001]. (B) cKit+Sca1+ contour plots after gati
treated mice [representative from 2 independent experiments, n = 5]. (C) Lin−Sca1+cKit+Flk
compared to vehicle controls [t-test, *p b 0.05 **p b 0.01]. (D) Enhanced survival of lethally
(B6+BALB/c) treated donors [pooled from two experiments, n = 10 per strain per group].S.F. is a postdoctoral fellow of the Crohn's and Colitis Foundation of
America (CCFA). W.G.K. is the Murphy Family Professor of Children's
Oncology Research, an Empire Scholar of the State University of NY
and a Senior Scholar of the CCFA.3. Results
3.1. Mobilization of an HS-PC Graft Capable of Long-Term, Multi-lineage
Repopulation and Radioprotection
We previously found that SHIP1 has a signiﬁcant role in HSC niche
function and in BM retention of HSC (Desponts et al., 2006; Hazen
et al., 2009, Iyer et al., 2014b). SHIP1-deﬁciency signiﬁcantly reduces
SDF1-CXCL12 expression by niche cells, increases G-CSF and MMP-9
production, and promotes signiﬁcant mobilization of HSC to theSDF1-CXCL12 concentrations are signiﬁcantly increased in the plasma of mice following
ng on Lin−Flk2− stem-progenitor population in the spleen and blood of SHIPi and vehicle
2− (LSKF−) HS-PC frequencies are signiﬁcantly increased in the spleen and blood of SHIPi
irradiated hosts transplanted with 7.5 × 105 WBC from 3AC-B6, 3AC-BALB/c or vehicle
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Wehypothesized that in vivo treatmentwith SHIPiwould have a similar
effect on the BM niche and HSC compartments. To determine this, wild
type (WT) mice were treated with SHIPi and blood was collected for
plasma cytokine analysis as well as phenotypic analysis of peripheral
tissues by ﬂow cytometry. Consistent with our observations in mice
with germline SHIP1 deﬁciency (Hazen et al., 2009) G-CSF and MMP-9
levels were profoundly increased and SDF1-CXCL12 levels were sig-
niﬁcantly reduced following SHIPi (Fig. 1A). SHIPi also triggered signiﬁ-
cant mobilization of Lin−Sca1+cKit+Flk2− (LSKF-) HS-PC population
(Christensen and Weissman, 2001) to the spleen and peripheral blood
(Fig. 1B, C). To determine whether the HS-PCs mobilized through
SHIPi treatment retained functional stem cell capabilities, we evaluated
the capacity of peripheral blood from SHIPi treated donors to protect re-
cipients from a lethal dose of radiation. Transplant of RBC lysed WBC
from both SHIPi treated B6 or BALB/c donors afforded signiﬁcant,
long-term survival to 65% (13/20) and 70% (7/10) of their respective
hosts (Fig. 1D). Importantly,WBC fromvehicle treated donors exhibited
no radioprotective capacity, consistent with the ﬁndings of MicklemFig. 2. SHIP1 inhibition enhances autologous engraftment followingminimally ablative conditio
ponents [WBC, neutrophils (NE), RBC and platelets (PLT)] are not dramatically decreased at 7
dependent experiments, 0 and 300 Rads n= 5, 1100 Rads n= 2, survival of all mice receiving 1
irradiated at 300 Rads on day 8 prior to transplant with 5 × 106 B6.1 congenic BM cells on day
congenic BM in the blood was signiﬁcantly higher in SHIPi vs vehicle-treated mice as determ
p b 0.0001]. Enhanced global (C) and lineage speciﬁc (D) repopulation of host with congenic
ﬂow cytometry plots for engraftment at 3 months post-transplant.et al. that murine peripheral blood lacks signiﬁcant HSC activity
(Micklem et al., 1975).
3.2. Facilitation of Congenic Transplantation at Non-ablative Radiation
Doses
Intense pre-conditioning regimens are currently required to deplete
the endogenous HSC compartment. This allows donor HSC to effectively
compete for space in the BM HSC niche in order to rapidly reconstitute
the hematolymphoid system. We considered that the mobilization of
Sca1+c-Kit+Lin−Flk2−HS-PC induced by SHIPi (Fig. 1B, C)might create
a space for engrafting HS-PC without the requirement for signiﬁcant
cytoablation. For this purpose, following SHIPi or vehicle treatment,
we conditioned B6.2 host mice using a minimally ablative dose of
300 Rads (Fig. 2A) prior to transplant with congenic B6.1 BM. We
found that even at these low radiation doses, SHIPi signiﬁcantly
improved long-term engraftment of congenic BM cells (Table 1,
Fig. 2B–E), as both global and lineage-speciﬁc engraftment of congenic
cells was increased in SHIPi relative to vehicle-treated hosts.ning. (A) Irradiation ofmice at 300 Rads isminimally ablative such that key blood cell com-
days post-irradiation [dashed line indicated lower end of normal range, pooled from 2 in-
100 Rad was b15 days.] (B–E) B6.2 hosts were treatedwith SHIPi or vehicle for 7 days and
s 8, 9 and 10 [pooled from two experiments using n = 5]. (B) Long-term engraftment of
ined by ﬂow cytometry [n = 9 SHIPi and n = 8 vehicle, mean ± SEM, 2-way ANOVA,
donor BM at 3 months post-transplant [t-test *p b 0.05, ***p b 0.001]. (E) Representative
Fig. 3. SHIPi treatment increases MDSCs, Tregs and decreases NK cell numbers and reduces their effector function. (A–E) B6.2 mice received indicated number of daily injection of SHIPi.
14 h after the last injection, splenocytes were harvested, counted and stained forMac1, Gr1, and NK1.1 or ﬁxed and stained for CD3ε, CD4, and FoxP3 and then analyzed by ﬂow cytometry
[mean ± SD, n = 5, 1-way ANOVA with Dunnett's Multiple Comparison Test between control (0 injections) and each time point, *p b 0.05, **p b 0.01, ***p b 0.001]. Mac1+Gr1+ double
positive cells (MDSC) reached signiﬁcantly higher frequencies (A) and absolute numbers (B) after 7 consecutive days of SHIPi treatment, as did the frequency of regulatory (CD4+FoxP3+)
T-cells (C). NK1.1+ cells were signiﬁcantly decreased starting at 2 daily injections and reached the lowest levels at 7 and 6 days of daily injections in terms of frequency (C) and absolute
numbers (D), respectively. (E–F) IFNγ production was measured via intracellular ﬂow cytometry on NKp46+CD3− splenocytes harvested from 6-day SHIPi or vehicle treated mice.
Splenocytes were stimulated with NK1.1 (center), PMA and ionomycin (right) or left unstimulated (Unstim., left) for 5 h prior to IFNγ staining and analysis [representative experiment
of three independent experiments is shown with n = 5, t-test **p b 0.01, *** p b 0.001]. (F) Representative ﬂow cytometry plots from E.
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210 S. Fernandes et al. / EBioMedicine 2 (2015) 205–2133.3. SHIPi Increases MDSC and Treg Cells and Causes Hyporesponsiveness
by the NK Cell Compartment
As mentioned previously, germline and induced SHIP-deﬁcient
mice are characterized by substantially increased numbers of MDSCs
(Ghansah et al., 2004; Paraiso et al., 2007) and Tregs (Collazo et al.,
2009) and display a severely compromised NK cell compartment
(Wahle et al., 2006; Wang et al., 2002; Fortenbery et al., 2010). More-
over, we had previously shown that treatment of WT mice with SHIPi
caused a dramatic increase inMDSCs in both the spleen andmesenteric
lymph node (Brooks et al., 2010). To extend these analyses, we
evaluated the effect of SHIPi treatment on splenic NK, Treg and MDSC
cell numbers. For this purpose, B6micewere treated daily for 10 consec-
utive days, and the frequency and absolute numbers of these cell types
were observed. As shown in Fig. 3A and B, both the frequency and the
absolute numbers of MDSC were signiﬁcantly increased by SHIPi and
reached a plateau after 7 days. While total T-cell numbers were slightly
decreased during the course of SHIPi (data not shown), the frequency of
CD4+FoxP3+ Treg cells was signiﬁcantly increased over the treatment
period (Fig. 3C). Concurrently, frequency and absolute number of NK
cells were dramatically reduced following 2 daily injections of SHIPi
and reached a nadir at 6–7 days as compared to controls (Fig. 3D, E).
Cytokine production after NK cell activation is a major effector function
of this cell type. NK cell effector function is compromised by SHIP1 deﬁ-
ciency in geneticmousemodels, includingwhen SHIP1 is selectively de-
leted in the NK cell lineage of NCR1CreSHIPﬂox/ﬂox mice (Gumbleton
et al., in press). To determine if SHIPi treatment results in NK cell hypo-
responsiveness,micewere treatedwith SHIPi for 6 days. On the seventh
day splenocytes were harvested and the ability of splenic NK cells to
produce IFNγ following ex vivo crosslinking of an activating receptor
was then assessed as a measurement of the functionality of the NK
cell compartment (Biron et al., 1999). SHIPi treatment of mice resulted
in signiﬁcantly lower production of IFNγ after NK1.1 receptor
crosslinking as compared to vehicle treated mice (Fig. 3F, G). Further-
more, NK cells from SHIPi treated mice also had signiﬁcantly lower
IFNγ production when treated with PMA and ionomycin. Therefore,
the NK cells in SHIPi treated mice display lower levels of effector
functions using both receptor-speciﬁc and unspeciﬁc stimulation.Fig. 4. SHIP1 inhibition and myeloablative conditioning reduces the immune barrier to MHC m
lethally irradiated (1100 Rads) on day 8, prior to transplant with 5 × 106 allogeneic BALB/c a
(CD45.1−, H2d+) and congenic (CD45.1+, H2d−) engraftment in the BM (left) and spleen (righ
frequency of allogeneic cells in the BM (B) and spleen (C) of SHIPi and vehicle treated hosts [p
differences were observed in congenic engraftment (not shown).These ﬁndings suggest they are in a state of general hyporesponsive-
ness. Taken together, the cellular milieu promoted by SHIPi treatment
could contribute to decreased allogeneic immune cell responses and en-
ables better engraftment of allogeneic HS-PCs.
3.4. SHIPi Facilitates Hematologic Recovery and Engraftment of MHC-I
Unmatched BM Grafts
To assess the effects of SHIPi treatment on allogeneic BM engraft-
ment,WTB6.2 hostswere treatedwith SHIPi or vehicle andwere lethally
irradiated prior to transplant with an equal mixture of congenic (B6.1)
and MHC-I mismatched (BALB/c) BM cells (Table 1). The frequency of
allogeneic cells found in BM and in the spleens of SHIPi or vehicle
conditioned hosts was assessed by ﬂow cytometry. Analysis of the
acute engraftment of the mixed BM graft revealed that SHIPi treatment
of host signiﬁcantly increased frequencies of H2d+ cells found in both
the BM (Fig. 4A left panels and B) and the spleen (Fig. 4A right panels
and C) as compared to vehicle controls. These ﬁndings suggest that
treatment with SHIPi reduced the acute rejection of the MHC-I
mismatched BM graft in this fully ablative setting. We then assessed
whether SHIPi facilitates engraftment of a mismatched MHC-I BM
graft without a congenic co-graft following fully ablative conditioning.
Using low doses of allogeneic BM (1 × 106 and 2 × 106 total cells,
Table 1), we observed that both short (Fig. 5A, B) and long-term
marrow repopulation activity (Fig. 5D) was improved relative to both
vehicle and steroidal controls (Fig. S1A–C). Increased allogeneic
engraftment at these low transplant doses was also reﬂected in signiﬁ-
cantly improved post-transplant survival (Fig. 5C), increased lineage
speciﬁc repopulation (Fig. 5E) and in accelerated recovery of all major
blood cell components (Fig. 5F–G, and Fig. S1D–E). Thus, SHIPi lowers
the immune barrier to engraftment following allogeneic BMT, consis-
tent with previous ﬁndings in genetically SHIP1-deﬁcient hosts (Wang
et al., 2002; Paraiso et al., 2007; Collazo et al., 2009; Wahle et al., 2006).
4. Discussion
Our previous studies in mice with germline or induced ablation of
SHIP1 expression suggested that chemical inhibition of SHIP1 in vivoismatched BMT. Host B6.2 mice were treated daily for 7 days with SHIPi or vehicle and
nd 5 × 106 congenic B6.1 BM cells. (A) Representative ﬂow cytometry plots of allogeneic
t) in SHIPi (top) or vehicle (bottom) treated hosts at 5 days post-transplant. (B–C) Relative
ooled from 2 experiments, n = 9 total, t-test ***p b 0.001, ****p b 0.0001]. No signiﬁcant
Fig. 5. SHIP1 inhibition andmyeloablative conditioning enhances long-term engraftment and survival following fullyMHCmismatched BMT. (A–G)Host B6.2micewere treated for 7 days
with SHIPi, vehicle, or steroidal control K190 and lethally irradiated (1100 Rads) on day 8, prior to transplant with 1 × 106 or 2 × 106 BALB/c BM cells. (A) Representative ﬂow cytometry
plots for engraftment in the blood at 7 days post-transplant of 1 × 106 allogeneic BM cells (H2Dd+, CD45.2+) in B6.2 hosts (H2Dd−, CD45.2+). (B) Percent engraftment in the blood at
7 days post-transplant measured by ﬂow cytometry following BMT with 1 × 106 BALB/c BM cells [for 3AC vs vehicle pooled from 2 experiments with n = 5, K190 vs vehicle, n = 4, as
in A] or 2 × 106 BALB/c BM cells [pooled from 3 experiments with n = 5] [t-test **p b 0.01]. (C) Enhanced survival of SHIPi vs vehicle or steroidal control-treated mice following
myeloablative and fully allogeneic BMT Mantel-Cox log rank tests of signiﬁcance from Kaplan–Meier survival curves, ***p b 0.001. Global (D) and lineage speciﬁc (E) repopulation at
3 months following myeloablative conditioning and allogeneic BMT in SHIPi vs vehicle conditioned hosts [2 × 106 BALB/c BM cells, 2 way-ANOVA ****p b 0.0001]. Enhanced recovery
of PLT (F) and RBC (G) following myeloablative conditioning and allogeneic BMT in SHIPi vs vehicle conditioned hosts [2 × 106 BALB/c BM cells, 2 way-ANOVA **p b 0.01]. Dotted line
marks lower end of normal range for each blood component.
211S. Fernandes et al. / EBioMedicine 2 (2015) 205–213might recapitulate genetic phenotypes that reduce the immune barrier
to allogeneic HSCT and or enhance mobilization of HSC (Wang et al.,
2002; Ghansah et al., 2004; Wahle et al., 2006; Desponts et al., 2006;
Paraiso et al., 2007; Collazo et al., 2009; Hazen et al., 2009). The study
presented here reveals that SHIPi does indeed modulate several key
components of the immune system (NK cells were shown to be
decreased and hyporesponsive, and MDSC and T regulatory cells were
signiﬁcantly increased) such that we observed considerably improved
marrow repopulating activity following transplant of allogeneic BM.
Consequently, inhibition of SHIP1 by small molecule therapeutics
could have a profound impact on the utility of allogeneic HSCT.
Indeed, brief inhibition of SHIP1 failed to display toxicity at doses that
allowed for improved engraftment in fully mismatched MHC-I BM
graft. By extension of these studies, eventually SHIP1 may prove to be
a valuable molecular target that could help facilitate allogeneic grafts
particularly for patients who lack an HLA matched donor.
Mobilization of HS-PCs by G-CSF administration as it is currently
practiced is a very effective and safe procedure. However, since a subset
of patients and donors fail to mobilize sufﬁcient numbers of HS-PCs to
permit engraftment, other alternatives such as CXCR4 antagonists
(AMD-3100) have been developed (Broxmeyer et al., 2005). Clinical tri-
als demonstrated that combining this antagonist, AMD3100-Plerixafor,
with G-CSF improved stem cell harvest and reduced the incidence of
failure (DiPersio et al., 2009a, 2009b). Nonetheless, even with this
combination of mobilizing agents, failure rates of ~7% are still observed
(Hosoba and Waller, 2014). New molecular targets are therefore
actively sought to further improve HSC mobilization for HSCT and
also in the treatment of vascular diseases (e.g. myocardial infarction,
peripheral artery disease or coronary artery disease), where periodic
HSC mobilization by G-CSF is believed to facilitate vascular repair
(Poole et al., 2013; Seiler et al., 2001). Our data show that SHIPi can
mobilize signiﬁcant numbers of HS-PC such that a single blood draw
from a donor can provide for radioprotection and long-term reconstitu-
tion in the majority of hosts. The SHIPi mobilized graft may therefore
represent a new methodology to mobilize patient or donor HSC for
HSCT therapies. This could be applied in settings where donors failG-CSF mobilization, or be used in concert with G-CSF and-or
AMD3100, to further increase the yield and efﬁciency of HS-PC mobili-
zation procedures.
Minimally ablative procedures in allogeneic HSCT have seen
increased utilization in various clinical settings, but there has also
been a concomitant increase in graft failure (Mattsson et al., 2008).
The mobilization of HS-PC triggered by SHIPi might also be used in
lieu of such cytoablative regimens, or perhaps in combination with
minimally ablative chemotherapeutic regimen to decrease the
incidence of graft failure. In several diseases, and particularly severe
autoimmune diseases, there is a growing effort to use autologous or
allogeneic BMT to ‘reboot’ the patient's immune system (Li and Sykes,
2012). However, HSCT can be associated with signiﬁcant morbidity
and mortality and thus is only utilized in the most severe cases. As the
SHIPi conditioning regimen we describe poses no signiﬁcant risk
to host viability (Brooks et al., 2010), we propose that SHIPi might
eventually enable a great proportion of patients to beneﬁt from these
autologous BMT procedures, at least in part by creating space in the
BM niche for engrafting HSC.
In our previous studies, it was observed that germline SHIP1
deﬁciency caused dramatic alterations in the receptor repertoire such
that rejection of MHC-I mismatched BM was severely compromised
(Wang et al., 2002; Wahle et al., 2006). More recently, NK cell-speciﬁc
deletion of SHIP1 has been shown to alter the receptor repertoire and
impair induction of INFγ upon receptor crosslinking (Gumbleton et al.,
in press). Moreover, SHIP1 deﬁciency in NK cells also enhances engraft-
ment of an MHC-I unmatched BM graft (Gumbleton et al., in press). In-
terestingly, both receptor speciﬁc and general activation of NK cells are
compromised by daily, extended treatmentwith SHIPi. Therefore, alter-
ations of SHIP1 signaling within the NK cell prevent rejection of cells
bearingmismatchedMHC-I antigens. Furthermore, it is well document-
ed that SHIP-deﬁciency, whether it be in germline (Ghansah et al.,
2004), induced (Paraiso et al., 2007) or triggered by SHIPi (Brooks
et al., 2010), causes a dramatic increase in MDSCs that can modulate
T-effector functions. Overall, the effects of SHIPi on the both the NK
and the myeloid cell compartments are believed to be the important
212 S. Fernandes et al. / EBioMedicine 2 (2015) 205–213factors in facilitating the observed increase in allogeneic BM engraft-
ment. Finally, germline SHIP-deﬁciency has been shown to cause in-
creased Treg cell numbers (Collazo et al., 2009; Ghansah et al., 2004;
Paraiso et al., 2007), and splenocytes from SHIPi treated mice and
SHIPi treated peripheral blood mononuclear cells (PBMC) display re-
duced priming of allogeneic responses in one-way mixed leukocyte re-
actions (Brooks et al., 2010).We propose that the signiﬁcant increase in
CD4+FoxP3+ regulatory T-cell frequency observed here also contribut-
ed to the immunoregulatory environment, which allowed for better en-
graftment of allogeneic BM grafts as host Treg cells can also promote
MHC-I mismatched BM engraftment (Fujisaki et al. 2011).
In summary, similarly to that observed in germline SHIP1-deﬁcient
mice, chemical inhibition of SHIP1 was observed to signiﬁcantly
enhance HS-PC mobilization and engraftment in a variety of settings,
including minimally ablative conditioning for autologous transplanta-
tion and in a fully ablative MHC-I mismatched setting. These ﬁndings
further conﬁrm a role for SHIPi in several aspects of HSCT and suggest
that SHIPi could prove to be an attractive therapeutic target to improve
HSCT outcomes.
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